Century Therapeutics, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
Century Therapeutics, Inc. (IPSC) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of -$109.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2026-08-12
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2026-06-30 was -$109.00K.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2026-03-31 was -$615.00K.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-12-31 was -$34.00K.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-09-30 was -$19.00K, a 101.77% decline year-over-year.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2025 was -$294.00K, a 292.16% decline from fiscal 2024.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2024 was $153.00K, a 94.12% decline from fiscal 2023.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2023 was $2.60M.
- Century Therapeutics, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2022 was -$1.79M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$109.00K 10-Q · filed 2026-08-12 | -$724.00K 10-Q · filed 2026-08-12 | -$758.00K derived: sum of 3 quarters · filed 2026-08-12 | -$777.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$615.00K 10-Q · filed 2026-05-13 | -$649.00K derived: sum of 2 quarters · filed 2026-05-13 | -$668.00K derived: sum of 3 quarters · filed 2026-05-13 | -$890.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$53.00K derived: sum of 2 quarters · filed 2026-03-12 | -$275.00K derived: sum of 3 quarters · filed 2026-08-12 | -$294.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$19.00K 10-Q · filed 2025-11-13 | -$241.00K derived: sum of 2 quarters · filed 2026-08-12 | -$260.00K 10-Q · filed 2025-11-13 | -$729.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$222.00K 10-Q · filed 2026-08-12 | -$241.00K 10-Q · filed 2026-08-12 | -$710.00K derived: sum of 3 quarters · filed 2026-08-12 | $365.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$19.00K 10-Q · filed 2026-05-13 | -$488.00K derived: sum of 2 quarters · filed 2026-05-13 | $587.00K derived: sum of 3 quarters · filed 2026-05-13 | $485.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $606.00K derived: sum of 2 quarters · filed 2026-03-12 | $504.00K derived: sum of 3 quarters · filed 2026-03-12 | $153.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.07M 10-Q · filed 2025-11-13 | $973.00K derived: sum of 2 quarters · filed 2025-11-13 | $622.00K 10-Q · filed 2025-11-13 | $2.07M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$102.00K 10-Q · filed 2025-08-14 | -$453.00K 10-Q · filed 2025-08-14 | $992.00K derived: sum of 3 quarters · filed 2025-08-14 | $897.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$351.00K 10-Q · filed 2025-05-15 | $1.09M derived: sum of 2 quarters · filed 2025-05-15 | $999.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.06M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $1.35M derived: sum of 2 quarters · filed 2025-03-19 | $1.41M derived: sum of 3 quarters · filed 2025-03-19 | $2.60M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$95.00K 10-Q · filed 2024-11-05 | -$36.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.16M 10-Q · filed 2024-11-05 | $2.31M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $59.00K 10-Q · filed 2024-08-08 | $1.25M 10-Q · filed 2024-08-08 | $2.40M derived: sum of 3 quarters · filed 2024-08-08 | $2.23M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-09 | $2.34M derived: sum of 2 quarters · filed 2024-05-09 | $2.18M derived: sum of 3 quarters · filed 2024-05-09 | $1.40M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $980.00K derived: sum of 2 quarters · filed 2024-03-14 | $200.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.79M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$165.00K 10-Q · filed 2023-11-09 | -$945.00K derived: sum of 2 quarters · filed 2023-11-09 | -$2.93M 10-Q · filed 2023-11-09 | -$3.52M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$780.00K 10-Q · filed 2023-08-09 | -$2.77M 10-Q · filed 2023-08-09 | -$3.35M derived: sum of 3 quarters · filed 2023-08-09 | -$3.39M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.99M 10-Q · filed 2023-05-11 | -$2.57M derived: sum of 2 quarters · filed 2023-05-11 | -$2.61M derived: sum of 3 quarters · filed 2023-05-11 | -$2.57M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$620.00K derived: sum of 2 quarters · filed 2023-03-16 | -$588.00K derived: sum of 3 quarters · filed 2023-03-16 | -$615.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | -$33.00K 10-Q · filed 2022-11-10 | -$1.00K derived: sum of 2 quarters · filed 2022-11-10 | -$28.00K 10-Q · filed 2022-11-10 | -$65.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $32.00K 10-Q · filed 2022-11-10 | $5.00K 10-Q · filed 2022-08-11 | -$32.00K derived: sum of 3 quarters · filed 2022-11-10 | -$111.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | -$27.00K 10-Q · filed 2022-11-10 | -$64.00K derived: sum of 2 quarters · filed 2022-11-10 | -$143.00K derived: sum of 3 quarters · filed 2022-11-10 | -$46.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2020-12-31 | -$37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$116.00K derived: sum of 2 quarters · filed 2022-03-17 | -$19.00K derived: sum of 3 quarters · filed 2022-03-17 | $8.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | -$79.00K 10-Q · filed 2021-11-10 | $18.00K derived: sum of 2 quarters · filed 2021-11-10 | $45.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $97.00K 10-Q · filed 2021-08-12 | $124.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |